AASK-CO

AASK-CO

• 批准号: 7378663
• 负责人: Otelio S Randall
• 金额: $ 14.34万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-15 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378663
• 关键词: clinical trials; hypertension; kidney

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK Clinical trial. The AASK trial was a randomized, clinical trial that tested the effects of 3 different medications used as first line hypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of BP control (usual and more aggressive control). Of the 1,094 randomized participants in AASK, it is estimated that Howard University will enroll 29 (of the 657-750 individuals who did not reach ESRD in the AASK Clinical Trial) in the AASK Cohort Study. Additionally, those AASK participants who reached ESRD will be invited to attend one visit for collection of DNA. Exposures to be collected twice/year for those in the AASK Cohort Study include environmental, genetic, physiologic and socioeconomic factors. The primary renal outcome will be a clinical outcome defined by the doubling of serum creatinine, progression to ESRD or death. Appropriate antihypertensive treatment (medications and target BP levels as determined by the AASK trial) will be provided to all participants who do not have ESRD. In this fashion, the Cohort will directly control two of the major "known" determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medications) and will, therefore, address its research objectives in the setting of recommended hypertensive care. It is anticipated that a minimum of 4 and a maximum of 6 contacts for BP control will take place per year for each participant. The anticipated duration of followup in the Cohort Study will be 5 years (total of 9-12 years, including the AASK Trial), and that the AASK Cohort Study will provide data that enhances our understanding of the processes that determine progression of renal disease. Furthermore, data from this study might ultimately lead to new prevention strategies that delay or prevent the onset of ESRD. Despite excellent BP control and use of reno-protective antihypertensive medication, hypertension-related renal disease commonly progresses. The primary objective of the AASK Cohort Study is to prospectively determine the long-term course of kidney function and risk factors for kidney disease progression in African Americans with hypertension-related kidney disease who receive recommended antihypertension therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors in the setting of hypertension-related kidney disease.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。 AASK队列研究是一项前瞻性，观察性研究，是AASK临床试验的扩展。 AASK试验是一项随机，临床试验，测试了3种用作第一线高血压疗法（Ramipril，Metoprolol和Amlodipine）和2个BP控制水平（通常，更具攻击性的对照）的作用。在AASK队列研究中，霍华德大学（Howard University）的1,094名随机参与者中，霍华德大学（Howard University）将招募29名（在AASK临床试验中未达到ESRD的657-750个人中，有29名。此外，将邀请那些到达ESRD的AASK参与者参加一次访问DNA的访问。在AASK队列研究中，每年两次收集的暴露包括环境，遗传，生理和社会经济因素。主要的肾脏结果将是血清肌酐，进展到ESRD或死亡的临床结果。将向所有没有ESRD的参与者提供适当的降压治疗（由AASK试验确定的药物和目标BP水平）。以这种方式，该队列将直接控制肾脏疾病进展的两个主要“已知”决定因素（高血压治疗和肾脏保护，降压药的使用），因此，将在推荐的高血压护理中解决其研究目标。预计每个参与者每年将每年进行至少4个和最多6个BP控制联系人。在队列研究中预期的随访时间将为5年（包括AASK试验，包括9 - 12年），并且AASK队列研究将提供数据，以增强我们对确定肾脏疾病进展的过程的理解。此外，这项研究的数据最终可能导致新的预防策略延迟或阻止ESRD的发作。 尽管BP控制良好并使用了肾脏保护性降压药，但与高血压相关的肾脏疾病通常仍在进行。 AASK队列研究的主要目的是前瞻性确定肾脏功能的长期过程和与高血压相关的肾脏疾病的肾脏疾病进展的危险因素，这些肾脏疾病进展，这些肾脏疾病接受了推荐的抗高血压疗法。第二个目标是确定心血管疾病的发生，并在与高血压相关的肾脏疾病的情况下评估其危险因素。